报价延迟最少15分钟:2025/09/17 10:06 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.87 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.57/-0.55
|
|
企业价值
209.98M
|
| 资产负债 |
|
每股账面净值
1.22
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
18.72M
|
|
每股收益
0.20
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/17 10:06 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib. |
